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Abstract
PRK1 is a member of the protein kinase C-related kinase (PRK) family of serine/threonine kinases and a downstream 
effector of Rho GTPases. PRK1 has three N-terminal Homology Region 1 (HR1) domains (HR1a, HR1b and HR1c), which 
form antiparallel coiled coils that interact with Rho family GTPases. PRK1 also has a C2-like domain that targets it to 
the plasma membrane and a kinase domain, which is a member of the protein kinase C superfamily. PRK1 is involved in 
cytoskeletal regulation, cell adhesion, cell cycle progression and the immune response, and is implicated in cancer. There 
is currently no structural information for the HR1c domain. The 1H, 15N and 13C NMR backbone and sidechain resonance 
assignment of the HR1c domain presented here forms the basis for this domain’s structural characterisation. This work 
will also enable studies of interactions between the three HR1 domains in an effort to obtain structural insight into the 
regulation of PRK1 activity.
Keywords Small GTPase · Protein Kinase C related kinase · PKN · HR1 domain · Coiled-coil
Biological context
Protein kinase C-related kinase 1 (PRK1) is a member 
of the PRK family of serine/threonine kinases, which is 
within the AGC group of kinases. The PRK proteins were 
first identified as effector kinases of the small G protein 
RhoA (Watanabe et al. 1996; Amano et al. 1996). Sev-
eral roles of PRK1 in cytoskeletal regulation have been 
described, including phosphorylation of vimentin (Mat-
suzawa et al. 1997), neurofilament assembly disruption 
(Manser et  al. 2008), interaction with the actin cross-
linking protein α-actinin (Mukai et al. 1997) and insulin-
induced stress fibre disruption (Dong et al. 2000). PRK1 
has also been linked to androgen receptor signalling and 
transcriptional regulation (Metzger et al. 2003, 2008), the 
immune response (Park et al. 2016), cell cycle progression 
(Schmidt et al. 2007), thromboxane signalling (O’Sullivan 
et al. 2015) and mTOR signalling (Yang et al. 2017; Wall-
roth et al. 2019). PRK1 is overexpressed in human prostate 
cancer (Metzger et al. 2003; O’Sullivan et al. 2017) and 
has also been implicated in ovarian cancer (Galgano et al. 
2009) and in the migration of bladder tumour cells (Lach-
mann et al. 2011).
PRK1 has three N-terminal HR1 domains, HR1a, HR1b 
and HR1c. These are antiparallel coiled coils of approxi-
mately 10 kDa that interact with the nucleotide-sensitive 
switch regions of Rho GTPases as shown in the structures of 
RhoA with HR1a (Maesaki et al. 1999) and Rac1 with HR1b 
(Modha et al. 2008). PRK1 also has a C2-like domain, which 
targets the protein to the plasma membrane (reviewed in 
Corbalán-García and Gómez-Fernández 2010) and a C-ter-
minal catalytic domain, which belongs to the protein kinase 
C family (reviewed in Pearce et al. 2010; Arencibia et al. 
2013; Chamberlain et al. 2014). The three HR1 domains 
together with the C2 domain comprise the regulatory region 
of the PRKs.
PRK1 is activated by phosphoinositide-dependent pro-
tein kinase 1 (PDK1) phosphorylation of its activation 
loop (Dong et al. 2000) and by lipids such as  PIP2,  PIP3 
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and arachidonic acid (Palmer et al. 1995; Mukai et al. 1994; 
Morrice et al. 1994; Kitagawa et al. 1995; Peng et al. 1996; 
Yu et al. 1997; Mukai and Ono 2006; Falk et al. 2014). 
Small GTPases like RhoA and Rac1 can also activate PRK1 
activity (Amano et al. 1996; Lu and Settleman 1999) and it 
is thought that RhoA binds to HR1a to relieve autoinhibi-
tion mediated by a pseudosubstrate region in this domain 
(Kitagawa et al. 1996).
The HR1a and HR1b domains both bind to Rho proteins 
and their structures have been characterised. There is cur-
rently no structural information on the HR1c domain and it 
is unknown whether this domain is structured and what role 
it plays in PRK1 regulation. There is also no information 
on the entire HR1 region and particularly on whether the 
three HR1 domains interact with each other or exist inde-
pendently in solution. Here we present the 1H, 15N and 13C 
NMR resonance assignment of the PRK1 HR1c domain. 
This will form the basis for structure determination and 
for investigating interactions between the three PRK1 HR1 
domains, providing much needed structural insight into 
PRK1 regulation.
Methods and experiments 
Protein expression and purification
Human PRK1 HR1c (residues 201–297) was expressed 
in pGEXHISP (Hutchinson et al. 2011) with a stop codon 
engineered to prevent the translation of the C-terminal  His6 
tag. The HR1c domain was expressed as a GST fusion in 
E.coli BL21 (DE3) Rosetta2 pLysS. Overnight cultures were 
diluted 1 in 10, grown at 37 oC to an  A600 of 0.8 and induced 
by adding 0.1 mM isopropyl β-d-1-thiogalactopyranoside. 
The cultures were then incubated at 20 oC for 20 h. For NMR 
experiments, isotopically labelled protein was produced 
by growing E.coli in M9 media supplemented with 1 g/L 
15NH4Cl (Sigma-Aldrich) and 3 g/L 13C-glucose (Cambridge 
Isotope Laboratories). The protein was purified using glu-
tathione agarose beads, eluted by adding HRV 3C protease 
to cleave the N-terminal GST-tag, further purified by size 
exclusion chromatography on a Superdex75 16/60 column 
(GE Healthcare) and concentrated in an Amicon Ultra-4 
Centrifugal Filter Unit (Millipore). Protein concentration 
was determined by amino acid analysis (Protein and Nucleic 
Acid Chemistry Facility, Department of Biochemistry, Uni-
versity of Cambridge).
NMR spectroscopy
NMR spectra were recorded at 298 K with 1.6 mM 
15N-labelled HR1c or 1.2 mM 15N, 13C-labelled HR1c in 
20 mM sodium phosphate pH 7.3, 150 mM NaCl, 0.05% 
 NaN3, 10%  D2O. 15N-HSQC, 15N-separated NOESY (150 
ms mixing time), 15N-separated TOCSY (60 ms mixing 
time), HNCA, HNCACB, HN(CO)CA, HN(CO)CACB, 
13C-HSQC and 13C-separated HCCH-TOCSY experiments 
were recorded on a Bruker DRX500. A 13C-separated 
NOESY experiment (100 ms mixing time) was recorded on 
a Bruker AV800. NMR data were processed using Azara 
(Wayne Boucher, University of Cambridge).
Backbone and side-chain resonance assignment was 
carried out in CCPN Analysis v2.3 (Vranken et al. 2005). 
Standard methodology (Gardner and Kay 1998) was used 
to carry out the backbone assignment using the 15N-sepa-
rated NOESY, 15N-separated TOCSY, HNCA, HNCACB, 
HN(CO)CA, HN(CO)CACB experiments with reference 
to the 15N-HSQC experiment. The 13C-separated HCCH-
TOCSY and 13C-separated NOESY experiments were used 
with reference to the 13C-HSQC, in addition to the above 
experiments, for the assignment of side-chain resonances. 
Side-chain amides were assigned using the 15N-separated 
NOESY and the 13C-separated NOESY. Aromatic side-
chains were assigned using the 15N-separated NOESY and 
the 13C-separated NOESY spectra with reference to the aro-
matic region of the 13C-HSQC spectrum.
Extent of assignment and data deposition
The PRK1 HR1c domain gave well-dispersed spec-
tra as shown by the quality of the 15N HSQC spectrum 
(δΗ = 6.4–10.1 ppm and δN = 104–126 ppm) (Fig. 1). The 
construct used includes PRK1 HR1c residues 201–297 and 
an additional 7 N-terminal residues (GPLGSHM) encoded 
by the expression vector, and the majority of resonances 
were assigned (Table 1). All the backbone NH resonances 
were assigned, with the exception of the His in the N-termi-
nal linker. All Asn and Gln  NH2 resonances were assigned. 
Nine out of the 10 expected Arg  HεNε peaks were observed 
in the HSQC (Fig.  1) but could not be unambiguously 
assigned, although one Arg  Hε was assigned in the 13C-sepa-
rated NOESY. All other sidechain resonances were assigned 
except those that rapidly exchange with the solvent: OH 
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groups, primary amines (N-terminal and Lys sidechains), 
Arg  Hη/Nη, and His  Hδ1/Nδ1 and  Hε2/Nε2.
A Chemical Shift Index (CSI) of + 1 or −1 was gener-
ated from the difference in backbone chemical shifts  (Cα, 
 Cβ and  Hα) from the random coil positions (Wishart and 
Sykes 1994). Figure 2 shows the short-range NOEs and 
the CSI for each residue. The backbone chemical shifts 
were also submitted to TALOS-N (Shen and Bax 2013) 
to predict the protein’s secondary structure, which is 
also shown in Fig. 2. Taken together the CSI, TALOS-
N and short-range NOEs allow the secondary structure 
to be determined. The data suggest that the PRK1 HR1c 
domain comprises three α-helices that are connected 
by short, unstructured regions. The first two helices are 
likely to form an anti-parallel coiled coil akin to other 
HR1 domains whose structures are known: the PRK1 
HR1a (Maesaki et al. 1999), PRK1 HR1b (Owen et al. 
2003), TOCA1 HR1 (Watson et al. 2016) and CIP4 HR1 
(Kobashigawa et al. 2009) domains. Chemical shift assign-
ment of the PRK1 HR1c domain will enable the structure 
determination using distance and torsion angle restraints 
determined from NMR experiments. The full backbone 
assignment will also allow investigation into inter-domain 
interactions between the three HR1 domains in PRK1. 
This will provide a structural understanding of how PRK1 
activity may be regulated. The chemical shifts have been 
deposited in the BMRB, accession number 50216.
Fig. 1  15N-HSQC recorded on 
1.6 mM 15N-labelled PRK1 
HR1c in 20 mM sodium 
phosphate pH 7.3, 150 mM 
NaCl and 10%  D2O on a Bruker 
DRX500 at 298 K. The assign-
ments are indicated for all 
assigned resonances. The argi-
nine side-chain  HεNε resonances 
are aliased in the 15N dimension 
and are indicated by an asterisk
Table 1  Extent of assignments of PRK1 HR1c
a Backbone only
Atom Number of 
expected
Number 
assigned
Percentage 
assignment
PRK1 HR1c HNa 98 97 99.0%
15NHa 104 97 93.3%
13Cα 104 104 100.0%
1Hα 104 104 100.0%
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Fig. 2  Summary of secondary structure of the PRK1 HR1c domain. 
The plot summarises the sequential and medium-range NOEs 
observed in 15N-separated and 13C-separated NOESY experiments. 
The height of the bars represents the strength of the following NOEs: 
(1)  dαN  (dαδ)—NOEs between  Hα of residue i and NH of residue i + 1 
or  Hδ of an i + 1 Proline; (2)  dNN  (dNδ)—NH of residue i and NH of 
residue i + 1 or  Hδ of an i + 1 Proline. The next 2 rows show the short-
range, i to i + 3 NOEs observed in α-helical regions. Δδ represents 
the chemical shift deviation from random coil for 13Cα, 13Cβ and 1Hα 
where the size of the bar represents the size of the shift deviation. The 
overall score for the secondary shifts, the chemical shift index (CSI), 
is represented as grey boxes. A value of + 1 denotes an extended, 
β-sheet-like structure and a value of −1 an α-helical structure. Sec-
ondary structure was predicted from the chemical shifts using 
TALOS-N and is shown with a cartoon representation
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